tirzepatide shortage fda The says the Zepbound is over. That's rattling the weight loss industry FDA reviews decision to put

Lilly reported the results Thursday in a news release, so the study results have not been peer reviewed or reported in a scientific journal

Among people who took a GLP-1 in the past but stopped, 22% say injections were the main reason they discontinued treatment, and 30% say injections were one of the reasons they stopped

The filing includes claims directed to potential use of the microorganism to preserve lean muscle mass in a human patient, including embodiments involving lactic acid bacteria such as Lactobacillus paracasei

Commerce Demand could shift away from obesity-promoting products to new healthier alternatives, creating opportunities across sectors